William C Kreisl

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    Brain 136:2228-38. 2013
  2. pmc A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 1026, USA
    J Cereb Blood Flow Metab 33:53-8. 2013
  3. pmc Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    Neuroimage 49:2924-32. 2010
  4. pmc Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy
    Jussi Hirvonen
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 1026, USA
    J Nucl Med 53:234-40. 2012
  5. pmc Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET
    Pavitra Kannan
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:2593-8. 2011
  6. pmc P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Nucl Med 51:559-66. 2010
  7. pmc Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET
    Amira K Brown
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland, USA
    J Nucl Med 49:2042-8. 2008
  8. doi request reprint The neurobiology of Alzheimer disease defined by neuroimaging
    Joseph C Masdeu
    Section on Integrative Neuroimaging, Clinical Brain Disorders Branch, NIMH, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Neurol 25:410-20. 2012

Collaborators

Detail Information

Publications8

  1. pmc In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    Brain 136:2228-38. 2013
    ..11)C-PBR28 may be useful in longitudinal studies to mark the conversion from mild cognitive impairment or to assess response to experimental treatments of Alzheimer's disease. ..
  2. pmc A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 1026, USA
    J Cereb Blood Flow Metab 33:53-8. 2013
    ..011). Our results show that TSPO genotype influences PBR28 binding in vitro and in vivo. Correcting for this genotype increased statistical power in our postmortem study and is recommended for in vivo positron emission tomography studies...
  3. pmc Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    Neuroimage 49:2924-32. 2010
    ..Non-binding may be differentially expressed in organs of the body. The relatively low in vivo specific binding of [(11)C]-(R)-PK 11195 may have obscured its detection of non-binding in peripheral organs...
  4. pmc Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy
    Jussi Hirvonen
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 1026, USA
    J Nucl Med 53:234-40. 2012
    ..In this study, we sought to determine whether in vivo expression of TSPO is increased ipsilateral to the seizure focus in patients with temporal lobe epilepsy...
  5. pmc Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET
    Pavitra Kannan
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 108:2593-8. 2011
    ..In summary, tariquidar and [(11)C]dLop can be used in combination to selectively measure the function of P-gp at the blood-brain barrier...
  6. pmc P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide
    William C Kreisl
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Nucl Med 51:559-66. 2010
    ..We examined the ability of (11)C-dLop to quantify P-gp function in humans after increasing doses of tariquidar, an inhibitor of P-gp...
  7. pmc Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET
    Amira K Brown
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland, USA
    J Nucl Med 49:2042-8. 2008
    ....
  8. doi request reprint The neurobiology of Alzheimer disease defined by neuroimaging
    Joseph C Masdeu
    Section on Integrative Neuroimaging, Clinical Brain Disorders Branch, NIMH, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Neurol 25:410-20. 2012
    ..Awareness of this fact has largely been driven by neuroimaging, and particularly by imaging amyloid β (abeta) deposition in the brain, a procedure approved by the US Food and Drug Administration for clinical use in April 2012...